Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

10.92 -0.10 (-0.91%)
Streaming Delayed Price Updated: 11:57 AM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oculis Holding AG - Ordinary shares

< Previous 1 2 3 Next >
News headline image
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q1 2026 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
From Oculis Holding AG
Via GlobeNewswire
News headline image
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Appoints Katie Kazem as Chief Legal Officer
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q3 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming November Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
From Oculis Holding AG
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.